Richard Blumenthal's STLN trades
- The latest STLN trade was a sale on Sep 23, 2026, when STLN closed at $6.82. It closed at $3.04 on Nov 20, 2026 (-55%).
Price changes use the closing price on each trade date, not the price actually paid, and ignore dividends. Filings report amounts only as ranges, so these figures show direction, not anyone's actual profit.
Richard Blumenthal reported 12 STLN transactions in 1 filing with the Senate eFD for 2025–2026: 0 purchases and 12 sales of Starling Oncology, Inc. - Common Stock, with trade dates from Sep 18, 2026 to Sep 23, 2026. The median gap between trade date and filing date is 34 days, and every trade was reported within 45 days.
- 12
- 0 / 12
- $96K to $390K
- 2026-10-26
STLN transactions reported by Richard Blumenthal
| Type | Owner | ||||
|---|---|---|---|---|---|
Starling Oncology, Inc. - Common Stock STLN | Sale | Spouse | $1,001 - $15,000 | 2026-10-26 #e67780bf-56e4-46f0-a81e-574a701dd539 | |
Starling Oncology, Inc. - Common Stock STLN | Sale | Spouse | $1,001 - $15,000 | 2026-10-26 #e67780bf-56e4-46f0-a81e-574a701dd539 | |
Starling Oncology, Inc. - Common Stock STLN | Sale | Spouse | $1,001 - $15,000 | 2026-10-26 #e67780bf-56e4-46f0-a81e-574a701dd539 | |
Starling Oncology, Inc. - Common Stock STLN | Sale | Spouse | $15,001 - $50,000 | 2026-10-26 #e67780bf-56e4-46f0-a81e-574a701dd539 | |
Starling Oncology, Inc. - Common Stock STLN | Sale | Spouse | $15,001 - $50,000 | 2026-10-26 #e67780bf-56e4-46f0-a81e-574a701dd539 | |
Starling Oncology, Inc. - Common Stock STLN | Sale | Spouse | $1,001 - $15,000 | 2026-10-26 #e67780bf-56e4-46f0-a81e-574a701dd539 | |
Starling Oncology, Inc. - Common Stock STLN | Sale | Spouse | $15,001 - $50,000 | 2026-10-26 #e67780bf-56e4-46f0-a81e-574a701dd539 | |
Starling Oncology, Inc. - Common Stock STLN | Sale | Spouse | $1,001 - $15,000 | 2026-10-26 #e67780bf-56e4-46f0-a81e-574a701dd539 | |
Starling Oncology, Inc. - Common Stock STLN | Sale | Spouse | $15,001 - $50,000 | 2026-10-26 #e67780bf-56e4-46f0-a81e-574a701dd539 | |
Starling Oncology, Inc. - Common Stock STLN | Sale | Spouse | $15,001 - $50,000 | 2026-10-26 #e67780bf-56e4-46f0-a81e-574a701dd539 | |
Starling Oncology, Inc. - Common Stock STLN | Sale | Spouse | $1,001 - $15,000 | 2026-10-26 #e67780bf-56e4-46f0-a81e-574a701dd539 | |
Starling Oncology, Inc. - Common Stock STLN | Sale | Spouse | $15,001 - $50,000 | 2026-10-26 #e67780bf-56e4-46f0-a81e-574a701dd539 |
A row is a disclosure, not an execution record: the filing reports a date, a bracket, and the reported owner, but not the price, share count, or reason. Compare the trade date with the filing date to see how long the transaction stayed private.
How long disclosure took
Days from trade date to filing date for 12 rows. The STOCK Act allows 30 days from notification and no more than 45 days from the trade. A late row is a timing fact, not evidence of wrongdoing.
- 0–15 days
- 0
- 16–30 days
- 0
- 31–45 days
- 12
- Over 45 days
- 0
- Median / longest
- 34d / 38d
Source documents
1 Senate eFD periodic transaction report, newest first. Each link opens the official filing.
- #e67780bf-56e4-46f0-a81e-574a701dd539Filed 2026-10-26 · 12 rows
What Richard Blumenthal's STLN filings don’t tell you
A disclosure row records a trade date, an amount bracket, and who owned the asset. It does not say why the trade was made, whether the position is still held, or anything about the business behind the ticker: revenue trends, margins, balance-sheet risk, or valuation. Those answers are in company filings, not congressional ones.
To work through a company yourself, use our stock research checklist. Members get the full version of that work: one sourced investment call a month, with the numbers and the risks that would change the view.
Members-only research
What members are reading this month
- Issue 09: Is Nvidia Stock a Buy at 10x Earnings Without Huang?
At $155.46, Nvidia trades at 9.8 times next year's expected earnings, about half the S&P 500's multiple. What the price assumes, and our three calls.
- Issue 08: Who Pays for a 5% Treasury? Stocks Hurt by Rising Rates
Homebuilders fall about five times as much as the S&P 500 when Treasury yields rise, and banks don't gain. Our 2026 rate screen, valuations and three calls.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchRichard Blumenthal and STLN: questions
Did Richard Blumenthal buy or sell STLN?
Senate eFD filings for 2025 and 2026 show 0 purchases and 12 sales of Starling Oncology, Inc. - Common Stock (STLN) reported by Richard Blumenthal, between 2026-09-18 and 2026-09-23. Reported owner: Spouse.
How much STLN did Richard Blumenthal trade?
Filings disclose brackets, not exact values. Summing the low and high ends of each bracket gives $96K to $390K across 12 transactions. Yield Theory does not estimate share counts, prices, or gains from these ranges.
When was the last STLN filing by Richard Blumenthal?
The most recent filing that includes a STLN trade was filed on 2026-10-26. New filings appear in the Senate eFD index and are picked up when the dataset is refreshed.
Yield Theory is not affiliated with any elected official or with Starling Oncology, Inc. - Common Stock. Rows are parsed from public Senate eFD periodic transaction reports; amounts are reported brackets and filings can be amended. This page is educational and is not investment advice.
Don’t copy the filing. Read the thesis.
Richard Blumenthal STLN disclosures are delayed, ranged, and often a spouse. Members get the monthly call that treats those rows as one input, then names catalysts, risks, and what would change the view. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included